BEIJING, Dec. 18, 2025 /PRNewswire/ — Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfullyBEIJING, Dec. 18, 2025 /PRNewswire/ — Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully

Syneron Bio Closes Nearly $100M in Series A and A+ Rounds

BEIJING, Dec. 18, 2025 /PRNewswire/ — Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully completed its Series A and A+ financing rounds, raising close to USD 100 million in total. Top-tier investors participated in the round, including AstraZeneca, AZ-CICC Healthcare Investment Fund, Pfizer Biotech Development Investment Fund, GL Ventures, 5Y Capital, Sinovation Capital, Lenovo Capital, Gree Capital and KHK fund.

Dr. Xiao Zhang, Founder and CEO of Syneron Bio, commented:
“We are honored to receive the recognition and support of leading global pharmaceutical companies and top-tier investment institutions. This financing will significantly strengthen the development of our intelligent high-throughput macrocyclic peptide development platform, Synova™, and provide the resources needed to advance multiple pipelines toward clinical stages.”

About Syneron Bio

Syneron Bio is a biotech company dedicated to the development of next-generation macrocyclic peptide therapeutics, employing its proprietary Synova™ platform. The company has built a robust pipeline targeting oncology and chronic diseases. With a team experienced in drug development and data science, Syneron Bio has completed multiple rounds of equity financing in less than three years, backed by multiple leading venture capital funds.

Company:Syneron Bio
Contact Person: Corrine.Chan
Email: corrine.chan@synerontech.com 
Telephone: 1801606886
City: Beijing

Cision View original content:https://www.prnewswire.com/news-releases/syneron-bio-closes-nearly-100m-in-series-a-and-a-rounds-302646092.html

SOURCE Syneron Bio

Market Opportunity
BIO Protocol Logo
BIO Protocol Price(BIO)
$0,04212
$0,04212$0,04212
-%4,55
USD
BIO Protocol (BIO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny

Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny

The post Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny appeared on BitcoinEthereumNews.com. The cryptocurrency world is buzzing with a recent controversy surrounding a bold OpenVPP partnership claim. This week, OpenVPP (OVPP) announced what it presented as a significant collaboration with the U.S. government in the innovative field of energy tokenization. However, this claim quickly drew the sharp eye of on-chain analyst ZachXBT, who highlighted a swift and official rebuttal that has sent ripples through the digital asset community. What Sparked the OpenVPP Partnership Claim Controversy? The core of the issue revolves around OpenVPP’s assertion of a U.S. government partnership. This kind of collaboration would typically be a monumental endorsement for any private cryptocurrency project, especially given the current regulatory climate. Such a partnership could signify a new era of mainstream adoption and legitimacy for energy tokenization initiatives. OpenVPP initially claimed cooperation with the U.S. government. This alleged partnership was said to be in the domain of energy tokenization. The announcement generated considerable interest and discussion online. ZachXBT, known for his diligent on-chain investigations, was quick to flag the development. He brought attention to the fact that U.S. Securities and Exchange Commission (SEC) Commissioner Hester Peirce had directly addressed the OpenVPP partnership claim. Her response, delivered within hours, was unequivocal and starkly contradicted OpenVPP’s narrative. How Did Regulatory Authorities Respond to the OpenVPP Partnership Claim? Commissioner Hester Peirce’s statement was a crucial turning point in this unfolding story. She clearly stated that the SEC, as an agency, does not engage in partnerships with private cryptocurrency projects. This response effectively dismantled the credibility of OpenVPP’s initial announcement regarding their supposed government collaboration. Peirce’s swift clarification underscores a fundamental principle of regulatory bodies: maintaining impartiality and avoiding endorsements of private entities. Her statement serves as a vital reminder to the crypto community about the official stance of government agencies concerning private ventures. Moreover, ZachXBT’s analysis…
Share
BitcoinEthereumNews2025/09/18 02:13
Mastercard Partners With Polygon to Enable Crypto Payments for Consumers and Merchants

Mastercard Partners With Polygon to Enable Crypto Payments for Consumers and Merchants

Mastercard is expanding its Crypto Credential system to self-custody wallets through a partnership with Polygon and Mercuyo. The firm has broadened its presence
Share
Crypto News Flash2025/12/19 19:03
USD holds firm despite soft November CPI – ING

USD holds firm despite soft November CPI – ING

The post USD holds firm despite soft November CPI – ING appeared on BitcoinEthereumNews.com. The US Dollar (USD) is proving surprisingly resilient despite the release
Share
BitcoinEthereumNews2025/12/19 19:08